Our study contributes to clarify the tumor suppressing function of miR-29 through forming a negative feedback loop of TRAF4/Akt signaling, and miR-29a represents a potent therapeutic target for treating gliomas. The gene discussed is AKT1; the disease is central nervous system cancer.